Cover Image
Read Now

Pharmacoeconomic review report: Latanoprostene bunod (Vyzulta) (Bausch Health Canada Inc.)

Latanoprostene bunod (LBN) 0.024% ophthalmic solution (Vyzulta) is indicated for the reduction of intraocular pressure (IOP) in patients with ocular hypertension (OHT) or open-angle glaucoma (OAG). It is available as a sterile topical ophthalmic solution containing 0.24 mg/mL LBN supplied in an eye-...

Full description

Bibliographic Details
Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) Canadian Agency for Drugs and Technologies in Health August 2019, 2019
Edition:Version: final
Series:CADTH common drug review
Subjects:
Canada
Ocular Hypertension / Drug Therapy
Glaucoma, Open-angle / Drug Therapy
Cost-benefit Analysis
Prostaglandins F, Synthetic / Therapeutic Use
Treatment Outcome
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
LEADER 02143nam a2200325 u 4500
001 EB001897171
003 EBX01000000000000001060176
005 00000000000000.0
007 tu|||||||||||||||||||||
008 200523 r ||| eng
245 0 0 |a Pharmacoeconomic review report: Latanoprostene bunod (Vyzulta)  |h Elektronische Ressource  |b (Bausch Health Canada Inc.) 
246 3 1 |a Latanoprostene bunod (Vyzulta) 
246 3 1 |a Pharmacoeconomic review report for Vyzulta 
250 |a Version: final 
260 |a Ottawa (ON)  |b Canadian Agency for Drugs and Technologies in Health  |c August 2019, 2019 
300 |a 1 PDF file (33 pages)  |b illustrations 
505 0 |a Includes bibliographical references 
653 |a Canada 
653 |a Ocular Hypertension / drug therapy 
653 |a Glaucoma, Open-Angle / drug therapy 
653 |a Cost-Benefit Analysis 
653 |a Prostaglandins F, Synthetic / therapeutic use 
653 |a Treatment Outcome 
710 2 |a Canadian Agency for Drugs and Technologies in Health 
041 0 7 |a eng  |2 ISO 639-2 
989 |b NCBI  |a National Center for Biotechnology Information 
490 0 |a CADTH common drug review 
856 4 0 |u http://www.ncbi.nlm.nih.gov/books/NBK549683  |3 Volltext  |n NLM Bookshelf Books  |3 Volltext 
082 0 |a 610 
520 |a Latanoprostene bunod (LBN) 0.024% ophthalmic solution (Vyzulta) is indicated for the reduction of intraocular pressure (IOP) in patients with ocular hypertension (OHT) or open-angle glaucoma (OAG). It is available as a sterile topical ophthalmic solution containing 0.24 mg/mL LBN supplied in an eye-drop dispenser with a 5 mL fill volume. The recommended dosage is one drop in the affected eye(s) once daily. At the manufacturer-submitted price of $26.25 per dispenser, LBN costs approximately $0.30 per day, assuming treatment of both eyes. The manufacturer submitted a cost-utility analysis comparing LBN with currently available prostaglandin analogues (PGAs) for the treatment of patients with OHT and OAG (bimatoprost 0.01%, bimatoprost 0.03%, generic latanoprost 0.005%, and travoprost 0.004%). All patients were assumed to have both eyes treated 

Similar Items